ArticleFrontiers in medicine2025
Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While blinatumomab has demonstrated substantial efficacy in relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), the therapeutic potential of combining blinatumomab with tyrosine kinase inhibitors (TKIs) and low-dose chemotherapy as frontline induction for newly diagnosed Philadelphia chromosome-positive B-ALL (Ph + B-ALL) remains systematically underexplored. This study aims to evaluate the efficacy and safety of blinatumomab in combination with low-dose chemotherapy for induction treatment of newly diagnosed Ph + B-ALL. Methods: A retrospective analysis was performed on 24 newly diagnosed cases of Ph + B-ALL admitted to the Department of Hematology at our institution, between April 2023 and April 2025. Result: The median age was 51.1 years in the blinatumomab group ( Conclusion: Blinatumomab combined with low-dose chemotherapy and TKIs demonstrated a trend toward improved MRD negativity, lower relapse rates, and reduced hematologic toxicity compared to conventional chemotherapy. These findings support further investigation in larger trials to confirm clinical benefit.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.